GlassScriptPhysician profile
David A Zink
NPI 1386690162
$4,857.40
in general payments reported to CMS, 2019-2025
22 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $317 · 2022: $453 · 2023: $1,374 · 2024: $1,125 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,934 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.98 |
| Education | $132.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,217.26 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $863.50 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $810.70 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.73 | 2019-2024 | Xifaxan |
| Pfizer INC. | $235.27 | 2019-2020 | |
| Genzyme Corporation | $180.97 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $169.04 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $147.03 | 2020-2025 | |
| Shionogi INC | $128.36 | 2019 | |
| Madrigal Pharmaceuticals | $109.45 | 2025 | Rezdiffra |
| Celgene Corporation | $97.31 | 2022-2024 | Zeposia |
| Covidien LP | $65.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.82 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $40.70 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $30.98 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $25.56 | 2025 | Ibsrela |
| Medtronic, INC. | $23.12 | 2023 | Nuvent |
| Ucb, INC. | $23.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.50 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $18.94 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $11.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.